| Bioactivity | SN52 is a potent, competitive, and cell-permeable inhibitor of NF-κB2. SN52 is a variant of the SN50 peptide and inhibits the nuclear translocation of p52-RelB heterodimers. SN52 has a strong radiosensitization effect on prostate cancer cells. SN52 can be used for cancer research[1]. | ||||||
| Invitro | SN52 (40 μg/ml; 30 mins before DMXAA) inhibits DMXAA-induced nuclear translocation of RelB in BMDCs[1].SN52 does not change the activation of canonical NF-κB signaling. The nuclear translocation of RelB is increased in DCs isolated from irradiated tumors, and SN52 abolishes this activation in activated DC cells[1].SN52 (40 μg/mL; 30 mins before co-cultured with irradiated or non-irradiated MC38 cells) inhibits the non-canonical NF-κB and increases Ifn-b expression in BMDCs stimulated with irradiated tumor cells[1]. | ||||||
| Name | SN52 | ||||||
| CAS | 1071173-56-2 | ||||||
| Shortening | AAVALLPAVLLALLAPVQRKRRKALP | ||||||
| Formula | C128H230N38O28 | ||||||
| Molar Mass | 2749.43 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture and light
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
SN52
CAS: 1071173-56-2 F: C128H230N38O28 W: 2749.43
SN52 is a potent, competitive, and cell-permeable inhibitor of NF-κB2. SN52 is a variant of the SN50 peptide and inhibi
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.